A novel, synthetic DNA vaccine developed at the Wistar Institute induces protective immunity against Mayaro virus (MAYV), a mosquito-borne infection endemic to South America, that has the potential to become a global emerging viral threat.
Severe fever with thrombocytopenia virus is an emerging tick-borne arbovirus first reported in East and Central China in 2009, and subsequently in Korea and Japan. A closely related virus, termed Heartland virus, was identified and isolated from two patients in the US in 2012.
Scientists have developed a novel vaccine platform which would allow the product to be ready for distribution and use in six weeks rather than the current six months.
Doubts are growing about whether the world’s emergency stockpile of 300,000 Ebola vaccine doses is enough to control future epidemics as the deadly disease moves out of rural forest areas and into urban mega-cities.
The Nebraska scientists used two forms of weakened Adenovirus to serve as vectors to deliver the Zika vaccine.
Researchers developed a lipid nanoparticle (LNP)-encapsulated modified mRNA vaccine encoding the POWV prM and E genes and demonstrated its immunogenicity and efficacy in mice following immunization with one or two doses.
For veterinarians and livestock producers, a custom vaccine isn’t an extravagance, but rather another tool in the box for addressing new or uncommon strains of livestock pathogens.
Researchers at the University of Hawaii medical school have successfully developed a vaccine candidate for the Zika virus, showing that it is effective in protecting both mice and monkeys from the infection.
Researchers compared the detection frequency of avian influenza H7 subtypes at live poultry markets in Guangdong Province, China, before and after the introduction of a bivalent H5/H7 vaccine in poultry. The vaccine was associated with a 92 percent reduction in H7 positivity rates among poultry and a 98 percent reduction in human H7N9 cases.
The Ministry of Health of the Democratic Republic of the Congo (DRC) announced, November 26, that a randomized control trial has begun to evaluate the effectiveness and safety of drugs used in the treatment of Ebola patients. The trial will form part of a multi-outbreak, multi-country study that was agreed to by partners under a World Health Organization (WHO) initiative.